Most variants of ACVRL1 in HHT are attributable to mutations in the conserved residues of the kinase domain, and there is often a loss of kinase activity that disrupts BMP9- and SMAD4-dependent signaling. The gene discussed is ACVRL1; the disease is hereditary hemorrhagic telangiectasia.